Get access

Current drugs in systemic lupus erythematosus

Authors

  • Yiyun Yu,

    1. Division of Rheumatology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095
    2. Division of Rheumatology, Huashan Hospital, Fudan University, Shanghai 200040, People's Republic of China
    Search for more papers by this author
  • Antonio La Cava

    Corresponding author
    1. Division of Rheumatology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095
    • Division of Rheumatology, David Geffen School of Medicine, University of California Los Angeles, 1000 Veteran Avenue 32-59, Los Angeles, CA 90095-1670
    Search for more papers by this author

Abstract

Systemic lupus erythematosus (SLE) is an autoimmune disease with heterogeneous presentation and clinical manifestations. These aspects represent a problem in the treatment of the disease. Nonspecific medications for SLE that include antimalarials, corticosteroids, and cytotoxic drugs improve the prognosis of SLE yet carry significant side effects. Therefore, new targeted therapies that block pathways involved in the pathogenesis of SLE have been developed as possible additions to the standard management of the disease. This work reviews the current therapies and novel approaches in the treatment of SLE. Drug Dev Res 72:561–572, 2011. ©2011 Wiley Periodicals, Inc.

Ancillary